The purpose of this study is to evaluate the efficacy and safety of Iodine-125 brachytherapy together with chemotherapy compared with surgical resection followed by concomitant radiochemotherapy in patients with newly diagnosed glioblastoma.
This is a prospective, multicentric open-label trial to evaluate the efficacy and safety of Iodine-125 brachytherapy together with chemotherapy compared with surgical resection followed by concomitant radiochemotherapy in patients with newly diagnosed glioblastoma. The primary efficacy outcome was evaluated with progression-free survival (PFS).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
84
Iodine-125: Iodine-125 if necessary, 0.6-0.8mCi, PD:120-150Gy Temozolomide: 75 mg per square meter of body-surface area per day, 7 days per week,42 days.
Surgical resection: Maximal surgical resection, including gross total resection, subtotal resection, and partial resection. Radiation: total 60 Gy, 2 Gy per daily fraction (Monday to Friday) for 6 weeks. Temozolomide: 75 mg per square meter of body-surface area per day, 7 days per week,42 days.
Progression-free survival (PFS)
PFS is defined as the time from randomization to progression or death from any causes. Progression is defined as the RANO Criteria indicated.
Time frame: 2.5 years after randomization
Overall Survival (OS)
OS is defined as the time from randomization to death from any causes.
Time frame: 2.5 years after randomization
Survival rates at 6 months and 1 year
The survival rates were measured at 6 months and 1 year
Time frame: at 6 months and 1 year after operation respectively
EORTC QLQ-C30
The Quality of life is measured with EORTC QLQ-C30 (The European Organization for Research and Treatment of Cancer Core Quality of Life questionnaire). The EORTC QLQ-C30 is designed to measure cancer patients' physical, psychological and social functions. The questionnaire is composed of multi-item scales and single items.
Time frame: 2.5 year after randomization
ECOG Performance Status
ECOG PS (Eastern Cooperative Oncology Group, performance status) is to assess how a patient's disease is progressing, and how the disease affects the daily living abilities of the patient, and determine appropriate treatment and prognosis. The scale is from 0 to 5. Higher scores mean a worse outcome.
Time frame: 2.5 year after randomization
Complications
Complications 1 week after operation were assessed. The complications after operation include headache, nausea, vomit, myodynamia, seizer, and so on.
Time frame: within 1 week after operation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.